POS-ARI-ER Observational Study of Acute Respiratory Infections

Condition(s) studied

Investigational drug(s) / intervention(s)

Data collection: Data collection from study participants to characterise diagnostic and therapeutic practices.

Study summary

Acute respiratory infections (ARI) are one of the most frequent reasons for hospital admission and antibiotic use, and can be caused by a broad range of pathogens, including respiratory viruses with proven epidemic potential, e.g. influenza and coronaviruses. The POS-ARI-ER study will focus on describing the different routine diagnostic and therapeutic practices in the work-up and treatment of ARI, as well as clinical outcomes across the patient population. In addition, POS-ARI-ER aims to characterise both the adult patient population with ARI presenting to acute hospital settings in Europe, and the aetiology of ARI in these patients.

Eligibility

Primary outcome measure(s)

• Proportion of adult patients undergoing ARI-relevant microbiology and virology investigations. — Four years
  Calculate the proportion of types of ARI-relevant microbiology and virology investigations performed.
• Proportion of adult patients receiving antibiotics, antivirals, antifungals and/or immunomodulators. — Four years
  Calculate the proportion of cases receiving antibiotics, antivirals, antifungals and/or immunomodulators.
• Clinical outcome of adults with community acquired ARI in acute hospital settings in Europe. — Last day in hospital, at death or 28 days after admission, whichever comes first.
  Maximal score using the ordinal scale assessed at discharge, death or at 28 days after hospital admission: 6= death, 5= hospitalisation requiring extracorporeal membrane oxygenation (ECMO) and/or invasive mechanical ventilation, 4= hospitalisation requiring non invasive ventilation (NIV) and/or high flow nasal cannula (HFNC) oxygen therapy, 3= requiring supplemental oxygen (but not NIV/HFNC), 2= hospitalisation not requiring supplemental oxygen, 1= not hospitalised.
• Length of hospital and/or ICU stay in adults with community acquired ARI in acute hospital settings in Europe. — Last day in hospital, at death or 28 days after admission, whichever comes first.
  Number of days patient admitted to hospital or ICU.
• Duration of NIV and IMV/ECMO in adults with community acquired ARI in acute hospital settings in Europe. — Last day in hospital, at death or 28 days after admission, whichever comes first.
  Number of days patients receiving NIV and IMV/ECMO.
• All cause mortality in adults with community acquired ARI in acute hospital settings in Europe. — Last day in hospital, at death or 28 days after admission, whichever comes first.
  Total number of deaths for each ARI-related pathogen.

Trial sites (23)

More European Clinical Research Alliance for Infectious Diseases (ECRAID) trials in Spain